Why the study?
Does AT1R blockade reduce VEGF-induced vascular hyperpermeability in mice?
Does AT1R blockade reduce VEGF-induced vascular hyperpermeability in mice?
AT1R blockade suppresses VEGF-induced vascular hyperpermeability, suggesting ARBs could be used to minimize edema risk during therapeutic angiogenesis.
AT1R blockade may limit VEGF-driven permeability in ischemic models; hypothesis-generating for ARBs in therapeutic angiogenesis.
OBJECTIVE: Permeability of blood vessels is essential for tissue homeostasis. However, disorganized hyperpermeability leads to progression of diseases. Vascular endothelial growth factor-A (VEGF) is a key regulator for leakiness of blood vessels and it has been reported that VEGF-mediated hyperpermeability was suppressed by angiopoietin-1 (Ang1). We found that Angiotensin-converting enzyme (ACE) was downregulated in endothelial cells by Ang1. ACE converts angiotensin I to angiotensin II (AII). Here, we studied the relationship between VEGF and AII relative to vascular permeability. METHODS AND RESULTS: We showed that VEGF-mediated vascular hyperpermeability was suppressed in mice given AII type 1 receptor (AT1R) blocker (ARB); the effect was also seen in AT1R-deficient mice. In this system, we found that ARB inhibited VEGF-induced gap formation. Furthermore, we ascertained that angioedema induced by overexpression of VEGF decreased noticeably in ARB-treated ischemic mice. CONCLUSIONS: Because ARB suppressed VEGF-induced vascular hyperpermeability, we propose that ARB may be used to minimize the risk of edema in therapeutic angiogenesis using VEGF.
No takes yet. Share an insight, caveat, or question.
Sano et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: